California health centers asked a federal district judge yesterday to stop a major state Medicaid drug reimbursement change due to begin tomorrow. They say the change would strip away all their 340B drug discount savings, devastating safety-net health care
…
Biopharmaceutical company AbbVie—maker of the expensive and widely prescribed immunosuppressive medication Humira—today became the 11th drug manufacturer to announce conditions on 340B pricing when contract pharmacies dispense medicines to patients.
Starting Feb. 1, AbbVie will require hospitals to submit claims
…
The federal government late yesterday filed notice that it is appealing a federal judge’s joint ruling in two cases last month that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and other health care providers
…
South Dakota U.S. Sen. John Thune, the second-ranking Senate Republican and a long-time 340B covered entity ally, might not run for re-election in 2022, two news organizations report. It would be a significant blow to 340B providers who have counted
…
U.S. Sen. Joe Manchin (D-W.Va.) has suggested that the U.S. Department of Veterans Affairs (VA) be empowered to negotiate drug prices on behalf of Medicare, an initiative that may impact the 340B program if it should come to fruition.
Manchin
…SPONSORED CONTENT
Confucius once said that “roads were made for journeys, not destinations.” Hudson Headwaters has been at the forefront of the 340B journey for 20 years while continuously leveraging field-driven experience to help clients effectively navigate and manage their 340B involvement. Our goal is to prevent the 340B program model from reaching an
…
The 340B Coalition said yesterday it is “actively exploring the potential for a hybrid [winter 2022] conference that would allow attendance in-person or virtually for those that cannot attend in-person.”
The coalition, composed of 13 groups that represent 340B covered
…
New York State and Virginia health centers asked a federal district judge on Monday to deny four insulin and diabetes drug manufacturers’ motion to pause fact-finding in the health centers’ antitrust suit stemming from the companies’ 340B contract pharmacy policies.
…
A federal appeals court in Philadelphia has given drug manufacturers Novo Nordisk and Sanofi a Jan. 26 deadline to file briefs seeking reversal of parts of a district judge’s Nov. 5 joint decision in the two companies’ 340B contract pharmacy
…
Drug manufacturer Boehringer Ingelheim (BI) this month extended its restrictions on 340B drug sales to hospitals to Ofev, its expensive specialty drug for idiopathic pulmonary fibrosis.
BI announced its new 340B pricing policy in late June. Effective Aug.
…*Sign up for news summaries and alerts from 340B Report
